Autolomous to provide Achilles Therapeutics with a digital solution to manage manufacturing of T cell therapy development

Autolomous to provide Achilles Therapeutics with a digital solution to manage manufacturing of T cell therapy development

London, UK, May 19, 2021 - Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, today announces it has signed a license agreement with Achilles Therapeutics plc (Nasdaq: ACHL), a clinical-stage biopharmaceutical company developing precision T-cell therapies to treat solid tumors.

Under the agreement, Autolomous will design, tailor and integrate a solution for Achilles using Autolomous’ platform, AutoloMATE™, a business critical robust digital solution for efficiency, scalability and process streamlining of the GMP manufacturing and product release of cell & gene therapies.  

“Whilst the manufacturing of cell and gene therapies expands in line with development in the sector, the management of the supply chain and manufacturing of these therapies is now essential. As a result, Autolomous now supports a range of advanced therapies throughout the industry, from dendritic-cell based cancer vaccines, CAR-T therapies and allogeneic NK therapies. Achilles will be Autolomous’ fifth partner, and adds precision T-cell therapies to this list,” said Alexander Seyf, CEO, Autolomous. “This partnership between Autolomous and Achilles will enable a tailored, end-to-end platform that integrates with all other elements of Achilles’ scalable manufacturing strategy, including moving towards a fully-closed commercial process. Autolomous will continue to deliver significant innovations to meet the needs of Achilles for managing the manufacturing of its T-cell therapies to treat solid tumors.”

Initial activity for the project will involve the deployment and integration of the Autolomous AutoloMATE platform to support GMP operations, including electronic batch manufacturing records. It is expected that the AutoMATE platform will support the expansion of Achilles’ manufacturing and streamline the overall vein-vein time. This bespoke, flexible platform is anticipated to support the continued evolution of Achilles pipeline of manufacturing processes.

About Autolomous
Autolomous LTD is the market leading developer of critical manufacturing management systems for cell and gene therapies. Autolomous internationally deploys fully integrated, digitized and automated supply chain software solutions. These solutions utilize emerging technologies such as Distributed Ledger technology and Internet of Things (IoT) to ensure compliance with current and future regulatory requirements. As a result, Autolomous enables manufacturers to reduce costs and deliver cell & gene therapies to more patients.         
Autolomous’ platform, AutoloMATE™ is a business-critical robust digital solution increasing efficiency, scalability and process streamlining of the GMP manufacturing and product release of cell & gene therapies.         
Autolomous LTD is headquartered in London. The company was founded in 2019 by four professionals with combined experience covering fifty years in advanced therapies and medical practice and thirty-five years in technology, software and business.